Arcutis Biotherapeutics Shares Drop Following Q3 Earnings Miss Due to Increased Expenses
Arcutis Biotherapeutics (ARQT) saw its stock price decline by nearly 20% on Thursday following the release of its third-quarter results. While the company reported a revenue increase of 45% year-over-year to $143.9 million—exceeding consensus estimates by $1.3 million—the bottom line fell short of analyst expectations due to higher operating expenses. The market reaction highlights investor sensitivity to rising costs despite strong top-line growth driven by the company's lead dermatology products. The discrepancy between revenue outperformance and earnings misses suggests that increased spending is currently outpacing the scaling benefits of their product sales.
Tickers: $ARQT
Topics: earnings miss revenue beat stock price drop
Read the full article at Seeking Alpha
Part of the story Redwire Shares Drop Following Q3 2026 Earnings Miss (29 articles)